SKB 518
Alternative Names: SKB-518Latest Information Update: 10 Jun 2024
At a glance
- Originator Sichuan Kelun Pharmaceutical Research Institute
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 24 May 2024 Preclinical trials in Solid tumours in China (Parenteral)
- 24 May 2024 Sichuan Kelun Pharmaceutical Research Institute plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease) in China (NCT06428331)